Organization
James Thoracic Oncology Center
4 abstracts
Abstract
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,
Abstract
Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.Org: James Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Columbus, OH, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.Org: AdventHealth Cancer Institute, Orlando, FL, James Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, University of California Davis Comprehensive Cancer Center, OncoC4,
Abstract
Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital & Solove Research Institute, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,